{"links":{"html":"https://www.erudio.com/reports/ideate-lung02-nct06203210","json":"https://www.erudio.com/reports/ideate-lung02-nct06203210.json","markdown":"https://www.erudio.com/reports/ideate-lung02-nct06203210.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"ideate-lung02-06203210"}},"request":"https://www.erudio.com/contact?report=ideate-lung02-06203210"},"offer":{"cited_commentary_sources":30,"verified_hcp_statements":159,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":20,"optional":true,"price_per_verified_person_usd":15,"price_usd":300,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"ideate-lung02-nct06203210"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=ideate-lung02-06203210","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/ideate-lung02-nct06203210","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-30T05:42:02.653857Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":9,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":6,"title":"Primary endpoint: Overall Survival (OS)"},{"claim_count":13,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":13,"title":"Secondary endpoints"},{"claim_count":16,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":12,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":26,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":12,"title":"Safety and tolerability"},{"claim_count":16,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":13,"title":"Design and conduct"},{"claim_count":32,"coverage":"discussed","id":"A1","source_count":13,"title":"Accelerated-approval sufficiency, withdrawal and a possible future filing"},{"claim_count":9,"coverage":"discussed","id":"A2","source_count":3,"title":"Dose selection and the perceived therapeutic window"},{"claim_count":12,"coverage":"discussed","id":"A3","source_count":2,"title":"CNS assessment, resistance work-up and localized relapse choices"},{"claim_count":15,"coverage":"discussed","id":"A4","source_count":5,"title":"Imdelltra exposure, delivery burden and the changing relapse benchmark"},{"claim_count":21,"coverage":"discussed","id":"A5","source_count":7,"title":"B7-H3 rationale, alternative ADCs, immune-instruction proposals and international applicability"},{"claim_count":20,"coverage":"discussed","id":"A6","source_count":8,"title":"Patient access, trial referral and adverse-event communication"}],"counts":{"cited_sources":32,"claims_by_expression_type":{"comparison":12,"experience":1,"interpretation":42,"opinion":34,"primary_context":6,"question":7,"restatement":27,"uncertainty":5,"unspecified":25},"claims_by_kind":{"interpretation":2,"protocol_statement":5,"publication_statement":1,"source_observation":151},"clinician_statements":71,"evidence_units":89,"findings":8,"organisational_accounts":7,"people_cited":25,"people_identity_verified":20,"people_total":27,"screened_sources":64,"verified_claims":159},"findings_index":[{"id":"F1","structure":{"claims":29,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":8,"views":18},"has_counterview":true,"limitations":5,"links":{"context":6,"support":33},"ma_question":true,"named_voices":12,"passages":14,"sources":10,"sources_by_kind":{"commentary":9,"media":1}},"title":"Fatal ILD makes tolerability a consequential, disputed judgment"},{"id":"F2","structure":{"claims":37,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":17,"views":16},"has_counterview":false,"limitations":3,"links":{"context":6,"support":42},"ma_question":true,"named_voices":15,"passages":22,"sources":19,"sources_by_kind":{"commentary":17,"publication":1,"registry":1}},"title":"Withdrawal shifts attention to randomized evidence without determining the program's outcome"},{"id":"F3","structure":{"claims":17,"claims_by_group":{"comparisons":5,"experience":0,"questions":0,"restated":6,"views":6},"has_counterview":true,"limitations":4,"links":{"context":2,"support":20},"ma_question":true,"named_voices":7,"passages":8,"sources":4,"sources_by_kind":{"commentary":4}},"title":"The relevant comparator depends on available therapy, prior exposure and delivery burden"},{"id":"F4","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":5,"views":5},"has_counterview":true,"limitations":4,"links":{"context":1,"support":12},"ma_question":true,"named_voices":4,"passages":8,"sources":4,"sources_by_kind":{"commentary":2,"media":1,"publication":1}},"title":"Dose reduction is proposed, but the perceived efficacy–toxicity window is narrow"},{"id":"F5","structure":{"claims":28,"claims_by_group":{"comparisons":2,"experience":1,"questions":1,"restated":9,"views":15},"has_counterview":false,"limitations":3,"links":{"context":4,"support":34},"ma_question":true,"named_voices":12,"passages":16,"sources":11,"sources_by_kind":{"commentary":10,"media":1}},"title":"Early systemic and CNS activity motivates development, with explicit limits on evidence maturity"},{"id":"F6","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":3,"views":5},"has_counterview":false,"limitations":3,"links":{"context":4,"support":12},"ma_question":true,"named_voices":6,"passages":12,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"Relapse work-up and disease distribution can redirect the treatment decision"},{"id":"F7","structure":{"claims":33,"claims_by_group":{"comparisons":4,"experience":0,"questions":2,"restated":9,"views":18},"has_counterview":true,"limitations":4,"links":{"context":2,"support":36},"ma_question":true,"named_voices":8,"passages":11,"sources":7,"sources_by_kind":{"commentary":5,"media":2}},"title":"B7-H3 optimism and proposed immune strategies extend beyond the I-DXd filing, without transferable proof"},{"id":"F8","structure":{"claims":17,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":3,"views":11},"has_counterview":false,"limitations":3,"links":{"context":0,"support":19},"ma_question":true,"named_voices":9,"passages":11,"sources":7,"sources_by_kind":{"commentary":6,"media":1}},"title":"The access gap drives early trial conversations and repeated patient-support needs"}],"medical_affairs_question":"What survival, durability, pulmonary-safety and delivery advantages would justify I-DXd at relapse, and for which prior-treatment groups?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Fatal ILD makes tolerability a consequential, disputed judgment"},{"id":"section-2","level":3,"title":"A contrasting interpretation proposes immune instruction rather than more cytotoxic exposure"},{"id":"section-3","level":2,"title":"Withdrawal shifts attention to randomized evidence without determining the program's outcome"},{"id":"section-4","level":2,"title":"The relevant comparator depends on available therapy, prior exposure and delivery burden"},{"id":"section-5","level":2,"title":"Dose reduction is proposed, but the perceived efficacy–toxicity window is narrow"},{"id":"section-6","level":2,"title":"Early systemic and CNS activity motivates development, with explicit limits on evidence maturity"},{"id":"section-7","level":2,"title":"Relapse work-up and disease distribution can redirect the treatment decision"},{"id":"section-8","level":2,"title":"B7-H3 enthusiasm motivates distinct research strategies, not transferable proof"},{"id":"section-9","level":2,"title":"The access gap drives early trial conversations and repeated patient-support needs"},{"id":"section-10","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":7},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":3},{"id":"F7","shared_claims":1}],"id":"T1","label":"Primary endpoint: Overall Survival (OS)"},{"findings":[{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":6},{"id":"F8","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":4},{"id":"F5","shared_claims":7},{"id":"F6","shared_claims":5},{"id":"F7","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F3","shared_claims":9},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":18},{"id":"F4","shared_claims":8},{"id":"F5","shared_claims":4},{"id":"F7","shared_claims":2}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":9},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":4},{"id":"F7","shared_claims":1},{"id":"F8","shared_claims":2}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-30T05:42:02.653857Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-30T05:58:45Z","record_hash":"d7123154dc54c81f223f2b910c608ad43f9457c6b33de8dddc2a5392e081f1ce","release_hash":"34b28c7ed1dfb77cb67a8a741847ef4109dfd80d40c1b84bbee8d3dd4db0cabc","report_id":"erudio-nct06203210","run_id":"20a2f41b-5703-486f-904a-70bafd5ec4df","schema_version":"5.0","slug":"ideate-lung02-06203210","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on IDeate-Lung02 in the sources reviewed for this edition leads to one open question: What survival, durability, pulmonary-safety and delivery advantages would justify I-DXd at relapse, and for which prior-treatment groups? Its leading findings: (1) fatal ILD makes tolerability a consequential, disputed judgment. (2) withdrawal shifts attention to randomized evidence without determining the program's outcome. (3) the relevant comparator depends on available therapy, prior exposure and delivery burden. 5 more findings follow. 64 sources screened, 32 cited; not all HCPs or all public discussion.","meta_description":"64 sources screened · 159 verified statements (71 from clinicians verified by NPI or staff page) from 32 sources · 8 findings. Updated Oct 30, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-30T05:58:45Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":64},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on reduced monitoring requirements and community feasibility of an alternative treatment for relapsed small cell lung cancer.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","86 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not representative of all HCP discussion. Unnamed references, differently rendered trial names and incompletely evaluated passages may leave relevant views absent.","The material mixes physician commentary with organizational, company-relay and public-account statements. Uncertain clinical roles and unnamed authors limit conclusions about clinician consensus.","Audio/video versions of one episode, duplicated posts and reposts should not be counted as independent agreement.","Earlier response, CNS and safety observations belong to IDeate-PanTumor01 or IDeate-Lung01, not to randomized IDeate-Lung02 efficacy results.","Reports of the phase 3 interruption do not provide the fatal-ILD count or incidence. Global recruitment interruption, a US partial hold and later reported continuation have different scopes and dates.","FDA's specific reason for finding the accelerated-approval evidence insufficient remains unresolved in these accounts. Suggested explanations involving available therapy, response durability, safety or design remain attributed interpretations.","The published design article and registry-based discussion differ on primary endpoint status. The sources do not establish the complete amendment history or whether an earlier filing-supporting analysis will occur.","Cross-trial comparisons differ by treatment line, geography, eligibility and time. They do not establish comparative efficacy, safety or absence of benefit.","A published study-design article is available, but no separate protocol document was listed with the registry material. Product-label coverage is incomplete, including no exact I-DXd or amrubicin label, so regulatory and treatment-availability commentary is not a comprehensive label assessment.","The rebiopsy statement is truncated, and the liquid-biopsy and subtype discussions do not provide a validated I-DXd treatment-selection rule."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":1,"other":0,"podcast":1,"publication":1,"registry":1,"regulatory":0,"x_thread":26,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":30,"methods":2},"count":32,"evidence_window":{"end":"2026-10-08","start":"2024-03-27"},"retrieval_snapshot":"2026-10-29T19:44:13.424260Z","timeline":[{"count":1,"week":"2024-W13"},{"count":2,"week":"2024-W36"},{"count":3,"week":"2025-W17"},{"count":1,"week":"2025-W26"},{"count":3,"week":"2025-W36"},{"count":1,"week":"2025-W37"},{"count":1,"week":"2025-W42"},{"count":3,"week":"2025-W51"},{"count":2,"week":"2025-W52"},{"count":1,"week":"2026-W01"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W06"},{"count":6,"week":"2026-W39"},{"count":5,"week":"2026-W40"},{"count":2,"week":"2026-W41"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT06203210:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06203210:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:41055143","quote_policy":"no_derivatives"},{"id":"openfda:b6019088-cd94-43b4-b5ce-ba20b6b8021e:20260114","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-bxzk4m7k4l4pqhhbb3guu3qx-3m3khnxwh3n2y","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-hvybly7ak5rfumcoeda5r4mx-3mavf27r5622w","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-imwn6ca64jxu7y6uzpy7rmgd-3m6fkib7cxs2u","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-t55lzfcrbvpl5linz44t6dic-3lnp6gct2is2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-t7xptfbayvic6qufjdwujti7-3lbmwiul4yk2y","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7512811489766993920","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:322442","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1745810737174294844:64b4fec6-e414-4826-a808-211c5c9acafd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1773107842532225495:e25562e7-e93e-4ba4-bce9-83d252ed5e92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1776312842955960540:9778c085-782c-424e-bb5f-90379e530d81","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1818980925033599211:26ea99c1-e3f7-4180-ab23-d782cb9cb36a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1818981528661020757:36dd202c-87d3-474a-ace5-98dbea8257f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1818982351185363046:745beeef-95ff-457c-8920-58838d3be46f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1818991519434686873:451e0c19-ed64-4ead-b795-b06f319891e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1819012285786186127:805aeffc-43d7-495d-99d8-76cce2206ad0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1819027449130402113:3db65125-b624-4444-a20d-212d8dd4705f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1819300456784605502:427d515e-b142-44d7-9d94-b0a154e9a85d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1819595382931824828:6228548f-5e7a-4211-9e88-0e2612544ba2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1820837629367136531:9d5b8c0f-0e35-4d74-85ad-3f651df21d72","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1822709641240801780:d58e935d-9357-4813-be8d-244b9248b656","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1825874685768208461:e4977a0e-0c52-4c20-928d-fd0ea62a274a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1832889715332415582:a74cc2b9-d6e8-4d24-bd68-956599f2dd73","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1832891892390109685:0239d244-ab5b-4626-a2e6-9efd0fc44645","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1843999797742895193:2a9b0898-958e-4d18-b442-62ce78f01752","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1853965623669207320:56954f8f-27ac-4a46-983a-9c5e88b0e719","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915165193069359203:866ab3c6-acac-42ef-9ad9-8377f4024a6d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916024345752711217:75ff13b1-9b7c-46f1-af9b-6005d758bee1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1938657499009175898:ae6eee62-a323-4a05-a463-40492e7d19ba","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964714435341164858:22e2b30e-0566-4809-85aa-5e416760680e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964739857605120297:41cf934e-93ba-4eed-aaf5-8809181bfded","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964741221135400997:12d3aaea-1062-4ce3-97df-d83fbb2873ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1978447470909870259:55de5192-932e-4bbe-8e26-abd6a2da2f63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979574135044080102:5e9cbea1-e77d-4013-863c-133e6fea28d5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1993037404928626965:e6d7f225-cbee-4fdd-b1a9-d118168271e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2001285072469569982:4e04cf9a-c55d-40f9-816e-a2d95616b5a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2001326394375328019:547618fb-dcab-4fcf-b5ab-f6dc523ef636","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2001719416128430366:0c554125-ae31-4553-b2fe-e54a9bf312ea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2001719538862141846:330ba5a4-4333-48f0-81a4-5e8ced96f5eb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2001725248673104248:2c6f8b11-d9ef-429a-a829-b1d91b4e0778","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2001725497240105411:cd78c412-28c7-4e50-a337-6b333d3f6091","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2004542368956191224:28707d65-a9fa-4837-b12a-a5583de92d7f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2004663762259767492:3c76f838-3d4b-40b8-88f4-ba52fbf6f92e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2005462872550522899:c118f901-741e-425c-823a-f9d99eaef1fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2011095772667002957:665d51e3-33be-4c93-b58c-5323804f797b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2011113508272775500:fb59687d-7d3c-4bcf-9934-ce14dffa0a68","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018345724765667479:b601c874-4dba-4682-b2c2-0ee08c13b16a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2075074855767056502:89bc109d-e1ba-4a1c-90cd-b5509ce64403","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098952287595212899:a3b13894-ca26-4afd-abff-4e14269b19ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103593203945378208:72aa5798-5396-495b-ab5e-8841f9a8c6a6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103626401861517784:e722a98e-f8ae-4463-953e-e4754d15b48f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103645777197441320:89428daf-81f6-49b1-a460-bbbb98c35c02","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103713455148802116:016afa16-92cb-43f6-ad84-83dd60d2e696","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103783150442737789:6bfe1584-3d97-4db1-ad0d-7fbc85e5f1ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103998894833328264:c88b8197-e001-4601-b604-dd08da31c288","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104306583396331769:6a756f83-4891-480d-9fd3-ebc4ee0f1390","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104778637870534897:30ebe7d3-8ef0-49ad-ac60-747efdcd8d26","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104834551025447183:4a978389-cd55-466d-81e6-39d3c3301801","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104931480124395741:17714e8d-1e9b-4378-aa34-875bdf3fef91","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105167884704215229:52adaca8-947c-47cc-bdd6-322a06c77e4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107979303090831374:9043aede-a36d-470b-bdec-f22edf8e70b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111487131717648633:6d4725b6-9572-4bbf-a8ee-eb9594360817","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114018695085478115:b0b3e0a7-6cb6-4d01-9e27-8572f5034096","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Y_cFhNbeN8U","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:beL0BmqbVUg","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":5,"linkedin_post":1,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":55,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":64},"count":64,"evidence_window":{"end":"2026-10-24","start":"2024-01-12"},"retrieval_snapshot":"2026-10-29T19:44:13.424260Z","timeline":[{"count":1,"week":"2024-W02"},{"count":1,"week":"2024-W13"},{"count":1,"week":"2024-W14"},{"count":8,"week":"2024-W31"},{"count":2,"week":"2024-W32"},{"count":1,"week":"2024-W34"},{"count":2,"week":"2024-W36"},{"count":1,"week":"2024-W41"},{"count":1,"week":"2024-W45"},{"count":1,"week":"2024-W47"},{"count":5,"week":"2025-W17"},{"count":1,"week":"2025-W26"},{"count":3,"week":"2025-W36"},{"count":1,"week":"2025-W37"},{"count":3,"week":"2025-W42"},{"count":2,"week":"2025-W48"},{"count":6,"week":"2025-W51"},{"count":3,"week":"2025-W52"},{"count":1,"week":"2026-W01"},{"count":1,"week":"2026-W02"},{"count":3,"week":"2026-W03"},{"count":1,"week":"2026-W06"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W37"},{"count":7,"week":"2026-W39"},{"count":5,"week":"2026-W40"},{"count":2,"week":"2026-W41"},{"count":2,"week":"2026-W42"},{"count":1,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"ifinatamab deruxtecan","slug":"ifinatamab-deruxtecan"},{"brand_names":["Hycamtin"],"label":"topotecan","slug":"topotecan"},{"reason":"Unmapped registry intervention: amrubicin","status":"unmapped"},{"reason":"Unmapped registry intervention: lurbinectedin","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Small cell lung cancer","slug":"small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"IDeate-Lung02","aliases":["IDeate-Lung02","A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)"],"brief_title":"A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","collaborators":["Merck Sharp & Dohme LLC"],"conditions":["Small Cell Lung Cancer"],"display_condition":"relapsed small cell lung cancer","display_interventions":[["ifinatamab deruxtecan"]],"enrollment":{"count":540,"type":"ESTIMATED"},"interventions":[{"name":"Ifinatamab deruxtecan","synonyms":["I-DXd"],"type":"DRUG"},{"name":"Topotecan","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Amrubicin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Lurbinectedin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06203210","official_title":"A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-01-30","type":"ESTIMATED"},"primary_endpoints":[{"description":"OS is defined as the time interval from the date of randomization to the date of death due to any cause.","measure":"Overall Survival (OS)","timeFrame":"From the date of randomization to the date of death due to any cause, up to approximately 3.7 years"}],"registered_date":{"date":"2024-01-12","type":"ACTUAL"},"registry_last_updated":"2026-08-06","registry_url":"https://clinicaltrials.gov/study/NCT06203210","short_name":"IDeate-Lung02","short_name_basis":"registry_acronym","sponsor":"Daiichi Sankyo","start_date":{"date":"2024-05-21","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"DS7300-188","type":"sponsor_study_id"},{"domain":"EU CT","id":"2023-509628-16-00","type":"ctis"},{"domain":"jRCT","id":"2031230631","type":"other"}],"study_type":"INTERVENTIONAL"}}}